Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 1.00 |
| ▸ | CDK4 | P11802 | 19/20 | 1.00 |
| ▸ | CCND1 | P24385 | 19/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 19/20 | 1.00 |
| ▸ | CDK7 | P50613 | 19/20 | 1.00 |
| ▸ | CCNH | P51946 | 19/20 | 1.00 |
| ▸ | CDK1 | P06493 | 16/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 16/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 10/20 | 1.00 |
| ▸ | CDK9 | P50750 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1378854 | 1.00 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CDK7 | |
| SCHEMBL1380073 | 0.94 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CDK7 | |
| SCHEMBL1380075 | 0.94 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CDK7 | |
| SCHEMBL1380899 | 0.94 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CDK7 | |
| SCHEMBL1380041 | 0.93 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CDK7 | |
| SCHEMBL1381821 | 0.93 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CDK7 | |
| SCHEMBL1381128 | 0.90 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CDK7 | |
| SCHEMBL1380702 | 0.90 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CDK7 | |
| SCHEMBL4487335 | 0.88 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CDK7 | |
| SCHEMBL4564826 | 0.88 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4787495-B2 | — | — | 2011-10-05 | — | — | JP | claimed |
| US-20090270427-A1 | PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-10-29 | — | — | US | claimed |
| US-20060183760-A1 | New purine derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-08-17 | — | — | US | claimed |
| EP-1534708-B1 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | CYCLACEL LTD (GB) | 2006-04-26 | — | — | EP | claimed |
| JP-2006509728-A | — | — | 2006-03-23 | — | — | JP | claimed |
| US-20050256142-A1 | 4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol;antiproliferative agents; viricides; alopecia; strokes; central nervous system diorders; neurodegenerative diseases; antidiabetic agents; mitosis; cyclin dependent kinase inhibitors; protein kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-11-17 | — | — | US | claimed |
| EP-1534708-A2 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | Cyclacel Limited (GB) | 2005-06-01 | — | — | EP | claimed |
| WO-2004016613-A2 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | CYCLACEL LIMITED (GB) | 2004-02-26 | — | — | WO | claimed |
| US-20090270427-A1 | PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270427-A1 | PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270427-A1 | PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-7544689-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-7544689-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-7544689-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-20060183760-A1 | New purine derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-08-17 | — | — | US | disclosed |
| EP-1534708-B1 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | CYCLACEL LTD (GB) | 2006-04-26 | — | — | EP | disclosed |
| US-20050256142-A1 | 4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol;antiproliferative agents; viricides; alopecia; strokes; central nervous system diorders; neurodegenerative diseases; antidiabetic agents; mitosis; cyclin dependent kinase inhibitors; protein kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-11-17 | — | — | US | disclosed |
| EP-1534708-A2 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | Cyclacel Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004016613-A2 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | CYCLACEL LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183760-A1 | New purine derivatives | C5, CYC1, CCNH | CDK2 261/4885CDK4 423/4885CCND1 86/4885 |
| US-20050256142-A1 | 4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol;antiproliferative agents; viricides; alopecia; strokes; central nervous system diorders; neurodegenerative diseases; antidiabetic agents; mitosis; cyclin dependent kinase inhibitors; protein kinase inhibitors | CDK1, CDK2, CCND1 | CDK2 2/4885CDK4 5/4885CCND1 3/4885 |
| US-20090270427-A1 | PURINE DERIVATIVES | C5, CYC1, CCNH | CDK2 214/4885CDK4 282/4885CCND1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.